Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Period	Net Profit Margin
2021-12-31	N/A
2022-12-31	N/A
2023-12-31	N/A
2024-12-31	-72.81%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DAWN	$21.48	+0.19%	1.33M
3
4
5

Day One Biopharmaceuticals Inc. (DAWN) Profit Margin

Profit Margin Data

Get Day One Biopharmaceuticals Inc. Data in Excel

More DAWN Financial Data